In search of markers of disease activity in patients with SLE we have investigated blood lymphocyte subsets from a large cohort of patient. Seventy-one patients were studied using a well-defined panel of fluorescent monoclonal antibodies which recognize the major T, B and NK lymphocyte subsets and activated cells. Flow cytometry was used with standard automated software.
Overall, SLE patients were lymphopenic. The proportion of activated T cells was increased and NK cells were decreased in both proportion and absolute numbers (P < 0.001). This decrease was more pronounced in the more active patients.
None of the T cell activation markers was shown to distinguish different degrees of disease activity. However, the percentage of NK cells was significantly reduced in active disease states (P< 0.01). Decreased numbers of NK cells could potentially reduce the resistance of SLE patients to infectious organisms.
WorralJG, SnaithML, BatchelorJR, IsenbergDA.SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up.Quart J Med1990; 275: 319–30.
2.
IsenbergDA, ColacoBC, DudeneyC, Todd-PokropekA, SnaithML.A study of the relationship between anti DNA antibody idiotypes and anticardiolipin antibodies with disease activity in systemic lupus erythematosus.Medicine (Baltimore)1986; 66: 46–55.
3.
Gonzalez-AmaroR, Alocer-VarelaJ, Alarcon-SegonoviaD.Natural killer cell activity in the systemic connective tissue diseases.J Rheumatol1988; 15: 1223–8.
4.
TothJ, StarsiaZ, BucM, StefanovicJ.Family study of natural killer cell activity in Clq-deficient patients with systemic lupus erythematosus-like syndrome: association between impaired natural killer cell function and C1q deficiency.Immunobiology1989; 180: 47–54.
5.
TrinchieriG.Biology of natural killer cells.Adv Immunol1989; 47: 187–376.
6.
TanEM, CohenAS, FriesJC. The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum1983; 25: 1271–7.
7.
IsenbergDA, ShonfeldY, SchwartzRS.Multiple serological reactions and their relationship to clinical activity in systemic lupus erythematosus; a study of 56 patients.Arthritis Rheum1984; 27: 132–8.
RaziuddinS, DanialHB, KelleyM.OKT4+ T cell abnormality in patients with active systemic lupus erythematosus: HLA-DR antigen expression.Clin Immunol Immunopathol1988; 48: 42–9.
10.
MorimotoC, ReinherzEL, SchlossmanSF, SchurPH, MillsJA, SteinbergAD.Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus.J Clin Invest1980; 66: 1171–4.
11.
SmolenJS, ChusedTM, LeisersonWM, ReevesJJP, AilingD, SteinbergAD.Heterogeneity of immunoregulatory T cell subsets in systemic lupus erythematosus. Correlation with clinical features.J Am J Med1982; 72: 783–90.
12.
DelfraissyJF, SegondP, GalanaudP, WallonC, MasiasP, DormontJ.Depressed primary in vitro antibody response in untreated systemic lupus erythematosus. T helper cell defect and lack of defective suppressor cell function.Clin Invest1980; 66: 141–8.
13.
McInerseyMF, CloughJD, SenitzerD, CathcartMK.Two distinct subsets of patients with systemic lupus erythematosus.Clin Immunol Immunopathol1988; 49: 116–32.
14.
MorimotoC, SteinbergAD, LetwinNL. A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demostrated with anti-2H4 antibody.J Clin Invest1987; 79: 762–8.
15.
TakeuchiT, TanakaS, SteibergAD, MatsuyamaT, SchlossmanSF, MorimotoC.Defective expression of the 2H4 molecule after autologous mixed lymphocyte reaction activation in systemic lupus erythematosus patients.J Clin Invest1988; 82: 1288–94.
16.
TanakaS, MatsuyamaT, SteinbergAD, SchlossmanSF, MorimotoC.Antilymphocyte antibodies against CD4+2H4+ cell populations in patients with systemic lupus erythematosus.Arthritis Rheum1989; 32: 398–405.
17.
GorlaR, AiroP, FranceschiniF. Decreased number of peripheral blood CD4+CD29+ lymphocytes and increased in vitro spontaneous production of anti-DNA antibodies in patients with systemic lupus erythematosus.J Rheumatol1990; 17: 1048–53.
18.
RemeT, PortierM, FrayssinouxF. T cell receptor expression and activation of synovial lymhocyte subsets in patients with rheumatoid arthritis.Arthritis Rheum1990; 33: 485–91.
19.
MagyarlakiT, LosonczyH, ParA.Comparison of some lymphocyte markers in B cell chronic lymphocytic leukaemia and systemic lupus erythematosus (the B lymphocyte subset).Haematohgia-Budap1990; 23: 110–20.
20.
KumagaiS, IshidaH, IwaiK. Possible different mechanisms of B cell activation in systemic lupus erythematosus and rheumatoid arthritis: opposite expression of low-affinity receptors for IgE (CD23) on their peripheral B cells.Clin Exp Immunol1989; 78: 348–53.
21.
HerbermanRB, WhitesideTL.The role of natural killer cells in human disease.Clin Immunol Immunopathol1989; 53: 1–23.
22.
FitzgeraldPA, MendelsonM, LopezC.Human natural killer cells limit replication of herpes simplex virus type 1 in vitro.J Immunol1985; 134: 2666–72.
23.
OrtaldoJR, OldhamRK, CannonGC, HerbermanRB.Specificity of natural cytotoxic reactivity of normal human lymphocyts against a myeloid leukemia cell line.J Natl Cancer Inst (USA)1977; 59: 77–82.
24.
Garcia-PenarrubbiaP, KosterFT, KelleyRO, McDowellTD, BankhurstAD.Antibacterial activity of human natural killer cells.J Exp Med1989; 169: 99–113.
25.
GinzlerEM, SchornK.Outcome and prognosis in systemic lupus erythematosus.Rheum Dis Clin North Am1988; 14: 67–78.
26.
Ter-BorgEJ, HorstG, LimburgPC, van RijwijkMH, KallenbergCG.C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study.J Rheumatol1990; 17: 1642–8.
27.
DeLuisA, PigrauC, PahissaA, FernandezF, Martinez-VazquezJM.Infection in 96 cases of systemic lupus erythematosus.Med Clin (Barc)1990; 94: 607–10.
